Trial reportNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
The effect of Gua Sha therapy on Parkinson's disease with rapid eye movement sleep behavior disorder: a randomized controlled trial.
Trial report in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To observe the clinical efficacy of Gua Sha therapy in treating Parkinson's disease (PD) with rapid eye movement sleep behavior disorder (RBD). A total of 52 PD patients with RBD were randomly assigned to the experimental group (n = 26) and the control group (n = 26). The control group was treated with conventional anti-PD drugs, and the experimental group was treated with Gua Sha therapy based on the control group. The RBDQ-HK, PDSS-2, MDS-UPDRSIII, HADS, and PDQ-39 scores were compared before treatment, at the end of 12 weeks of treatment, and 2 months of follow-up. Before treatment and at the end of 12 weeks of treatment, polysomnography (PSG) was performed to record related sleep parameters, and the changes in serum Lp-PLA2, IL-1β, PGE2, Glu and NT-3 were observed. After treatment, the symptoms of sleep disorder, motor function, emotional disorder, and quality of life in the experimental group were significantly improved, the levels of Lp-PLA2, IL-1β, and PGE2 were decreased, the levels of Glu and NT-3 were increased, and the curative effect was better than that in the control group (P < 0.05). No serious adverse events occurred. The efficacy of Gua Sha therapy in the treatment of PD with RBD is precise and has good safety, which is worthy of clinical application.
Indexed as
Identifiers
40608228What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.